Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.

Harwood, Matthew; Hodges, Georgina; Tan, Xuan; Cheah, Chan Y; Lim, Kenneth; Ku, Matthew; Tam, Constantine; Lagerlof, Ingemar; Cochrane, Tara

Harwood, Matthew; Hodges, Georgina; Tan, Xuan; Cheah, Chan Y; Lim, Kenneth; Ku, Matthew; Tam, Constantine; Lagerlof, Ingemar; Cochrane, Tara.

Afiliação

Harwood M; Gold Coast University Hospital, Southport, Australia.
Hodges G; Townsville University Hospital, Townsville, Australia.
Tan X; Sir Charles Gairdner Hospital, Nedlands, Australia.
Cheah CY; School of Medicine, University of Western Australia, Perth, Australia.
Lim K; Sir Charles Gairdner Hospital, Nedlands, Australia.
Ku M; School of Medicine, University of Western Australia, Perth, Australia.
Tam C; St Vincent's Hospital Melbourne, Fitzroy, Australia.
Lagerlof I; St Vincent's Hospital Melbourne, Fitzroy, Australia.
Cochrane T; School of Medicine, University of Melbourne, Fitzroy, Australia.

Leuk Lymphoma ; 61(14): 3412-3416, 2020 12.

Article em En | MEDLINE | ID: mdl-32856509

Assuntos

Doença de Hodgkin; Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico; Ciclofosfamida/uso terapêutico; Etoposídeo/uso terapêutico; Doença de Hodgkin/tratamento farmacológico; Humanos; Recidiva Local de Neoplasia/tratamento farmacológico; Recidiva; Terapia de Salvação; Resultado do Tratamento; Vincristina/uso terapêutico

Palavras-chave

Lymphoma and Hodgkin disease; chemotherapeutic approaches; eBEACOPP; immunotherapy; novel; relapsed/refractory

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Hodgkin Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google